COMPASS Pathways plc(纳斯达克代码:CMPS)今日正式披露2025财年第四季度及全年财务报告,同步公布重要业务进展。公司核心研发项目COMP360裸盖菇素疗法获得突破性临床数据,抑郁症治疗三期试验患者入组完成率达行业领先水平。现金储备优化至3.2亿美元,为2026年关键研究提供资金保障。管理层将于美东时间上午8点召开业绩电话会议。
COMPASS Pathways plc(纳斯达克代码:CMPS)今日正式披露2025财年第四季度及全年财务报告,同步公布重要业务进展。公司核心研发项目COMP360裸盖菇素疗法获得突破性临床数据,抑郁症治疗三期试验患者入组完成率达行业领先水平。现金储备优化至3.2亿美元,为2026年关键研究提供资金保障。管理层将于美东时间上午8点召开业绩电话会议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.